article · JAIDS Journal of Acquired Immune Deficiency Syndromes

Pharmacokinetics of Dolutegravir in Children with HIV with and without Tuberculosis Coinfection Treated According to World Health Organization Dosing Guidelines

Awewura Kwara
Augustina Frimpong Appiah
Priscilla Asiedu
Eugenia Sly-Moore
Aikins Kofi Amissah
Oluwayemisi Ojewale
Ama Darkoaa Sarfo
Dennis Bosomtwe
Nicole Maranchick
Theresah Opoku
Hongmei Yang
Charles Martyn-Dickens
Isaac Kusi-Amponsah
Charles A. Peloquin
Anthony Enimil
Albert Dompreh
Sampson Antwi

2026Kwame Nkrumah University of Science and Technology

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

Twice-daily dolutegravir with rifampin was associated with higher trough concentrations in children with HIV/TB than in controls. Standard dose of dolutegravir with rifampin needs to be investigated.

Research topics

HIV/AIDS drug development and treatment
Tuberculosis Research and Epidemiology
Pneumocystis jirovecii pneumonia detection and treatment

Sustainable Development Goals

Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1097/qai.0000000000003862

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.